Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Huiwen
LEAP2MONO, NCT05222906 / 2021-005402-10: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3	Active, not recruiting	3	43	Europe, Canada, Japan, US, RoW	Venglustat, imiglucerase, Cerezyme®	Sanofi, Sanofi-aventis recherche & développement	Gaucher's Disease Type III	09/25	10/26
NCT06703879: Machine Learning-Based Model for Individualized Drug Dose Prediction for Propofol	Not yet recruiting	N/A	1000	RoW	Anesthesia induction with propofol, Induction of anesthesia by intravenous infusion of propofol	General Hospital of Ningxia Medical University	Anesthesiology, Anesthesiology Management	03/25	06/25
Drelichman, Guillermo
LEAP2MONO, NCT05222906 / 2021-005402-10: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3	Active, not recruiting	3	43	Europe, Canada, Japan, US, RoW	Venglustat, imiglucerase, Cerezyme®	Sanofi, Sanofi-aventis recherche & développement	Gaucher's Disease Type III	09/25	10/26
Yakimoski, Amy
LEAP2MONO, NCT05222906 / 2021-005402-10: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3	Active, not recruiting	3	43	Europe, Canada, Japan, US, RoW	Venglustat, imiglucerase, Cerezyme®	Sanofi, Sanofi-aventis recherche & développement	Gaucher's Disease Type III	09/25	10/26
Shi, Yawen
LEAP2MONO, NCT05222906 / 2021-005402-10: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3	Active, not recruiting	3	43	Europe, Canada, Japan, US, RoW	Venglustat, imiglucerase, Cerezyme®	Sanofi, Sanofi-aventis recherche & développement	Gaucher's Disease Type III	09/25	10/26